Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 2-AI or 2C-B or Carbamazepine

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Tegretol (IR, XR, suspension), Carbatrol (ER), Equetro (ER for bipolar), Epitol (1)
classes:
2C-x series (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · Stimulant (1) · [[:Category:Anticonvulsants|Anticonvulsant]] (1) · [[:Category:Mood stabilizers|Mood stabilizer]] (1) · [[:Category:Sodium channel blockers|Sodium channel blocker]] (1)
mechanism:
None (1) · 5-HT2A partial agonist (1) · Alpha-methylated amphetamine analogue; norepinephrine releasing agent (1)
uses:
None (2) · '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1)
starting dose:
None (2) · Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day (1)
preparations:
None (2) · IR tablets 200 mg; chewable 100 mg; oral suspension 100 mg/5 mL; XR tablets 100, 200, 400 mg (Tegretol XR); ER capsules 100, 200, 300 mg (Carbatrol, Equetro) (1)
fda max:
None (2) · 1200 mg/day (adult seizures); 1600 mg/day (bipolar mania) (1)
routes:
None (1) · insufflated (1) · Oral (2) · PR (1)
onset:
None (1) · 45-75 min (oral) (1) · Anticonvulsant effect within days; trigeminal neuralgia relief 24-72 hours; mood-stabilizing effect over weeks (1)
duration:
None (1) · 4-8 h (1) · BID-QID dosing (IR); BID for ER formulations (1)
halflife:
None (1) · '''Autoinduction''': 25-65 hours initially, falling to 12-17 hours after 2-3 weeks of dosing as carbamazepine induces its own CYP3A4 metabolism. Major clinical implication: doses require re-titration after the autoinduction period'"`UNIQ--ref-0000001D-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (1) · Not well characterized (1) · ~80% (oral)'"`UNIQ--ref-0000001E-QINU`"' (1)
pregnancy:
None (1) · '''Substantial teratogenic risk''' including neural tube defects, craniofacial malformations, cardiac defects, and growth restriction; folic acid supplementation and effective contraception are required in reproductive-age patients'"`UNIQ--ref-0000001F-QINU`"' (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"